We are live on
!
Find out more
MWNA
Marshall Wace North America Portfolio holdings
AUM
$23.5B
1-Year Est. Return
46.46%
This Fund
S&P 500
This Quarter
Est. Return
+9.94%
1 Year Est. Return
+46.46%
3 Year Est. Return
+109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$24.1B
AUM Growth
-$134M
(-0.56%)
Cap. Flow
-$2.11B
Cap. Flow
% of AUM
-8.76%
Top 10 Holdings %
Top 10 Hldgs %
23.77%
Holding
1,984
New
527
Increased
347
Reduced
445
Closed
587
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$157M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$135M |
| 3 |
Salesforce
CRM
|
+$135M |
| 4 |
IBM
IBM
|
+$130M |
| 5 |
Dell
DELL
|
+$114M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$313M |
| 2 |
Apple
AAPL
|
+$207M |
| 3 |
Intel
INTC
|
+$183M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$159M |
| 5 |
Centene
CNC
|
+$152M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.31% |
| 2 | Technology | 17.95% |
| 3 | Communication Services | 13.61% |
| 4 | Consumer Discretionary | 12.67% |
| 5 | Financials | 8.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PPL
576
PPL Corp
PPL
$26.7B
| $4.51M | 0.02% |
161,310
-66,676
| -29% | -$1.93M |
|
|
GRNA
577
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
| $4.5M | 0.02% |
458,576
| – | – |
|
578
BlueLinx
BXC
$706M
| $4.49M | 0.02% |
89,288
+72,239
| +424% | +$3.55M |
|
579
Aemetis
AMTX
$124M
| $4.48M | 0.02% |
400,967
+357,312
| +818% | +$5.63M |
|
|
HIBB
580
DELISTED
Hibbett, Inc. Common Stock
HIBB
| $4.48M | 0.02% |
+49,939
| New | +$3.9M |
|
581
Liberty Global Class C
LBTYK
$3.49B
| $4.47M | 0.02% |
165,468
-110,741
| -40% | -$2.99M |
|
|
JWSM
582
DELISTED
Jaws Mustang Acquisition Corp.
JWSM
| $4.46M | 0.02% |
+456,600
| New | +$4.5M |
|
|
IPOF
583
DELISTED
Social Capital Hedosophia Holdings Corp. VI
IPOF
| $4.44M | 0.02% |
+435,170
| New | +$4.49M |
|
584
Grove Collaborative
GROV
$46.1M
| $4.41M | 0.02% |
+90,000
| New | +$4.42M |
|
|
MYOV
585
DELISTED
Myovant Sciences Ltd.
MYOV
| $4.39M | 0.02% |
+192,994
| New | +$4.06M |
|
586
GCM Grosvenor
GCMG
$820M
| $4.38M | 0.02% |
+420,653
| New | +$4.97M |
|
|
FCAX
587
DELISTED
Fortress Capital Acquisition Corp.
FCAX
| $4.36M | 0.02% |
443,385
| – | – |
|
588
Cognizant
CTSH
$26B
| $4.36M | 0.02% |
+62,934
| New | +$4.69M |
|
|
NAPA
589
DELISTED
The Duckhorn Portfolio, Inc.
NAPA
| $4.34M | 0.02% |
196,658
+110,865
| +129% | +$2.16M |
|
590
Oneok
OKE
$54.5B
| $4.34M | 0.02% |
77,946
+58,225
| +295% | +$3.1M |
|
591
Huntington Bancshares
HBAN
$35.5B
| $4.33M | 0.02% |
+303,622
| New | +$4.65M |
|
592
Atlassian
TEAM
$37.8B
| $4.3M | 0.02% |
+16,760
| New | +$3.92M |
|
593
KB Financial Group
KB
$43.5B
| $4.29M | 0.02% |
87,103
+48,410
| +125% | +$2.42M |
|
|
ONCR
594
DELISTED
Oncorus, Inc.
ONCR
| $4.28M | 0.02% |
309,894
| – | – |
|
595
Xometry
XMTR
$5.34B
| $4.28M | 0.02% |
+48,934
| New | +$4.28M |
|
|
FOE
596
DELISTED
Ferro Corporation
FOE
| $4.26M | 0.02% |
+197,690
| New | +$3.89M |
|
|
SEM
597
DELISTED
Select Medical
SEM
| $4.24M | 0.02% |
186,253
-342,753
| -65% | -$7.11M |
|
598
FirstEnergy
FE
$27.5B
| $4.22M | 0.02% |
113,347
+78,714
| +227% | +$2.93M |
|
599
Deutsche Bank
DB
$71.5B
| $4.19M | 0.02% |
+320,437
| New | +$4.35M |
|
|
KSU
600
DELISTED
Kansas City Southern
KSU
| $4.17M | 0.02% |
14,697
-48,693
| -77% | -$14.1M |
|
Similar funds
TGHSA
PAM
HB
MWA
3SCA
HFCIV
DVC
NAM
Marshall Wace North America's Q2 2021 Portfolio in Review
As of Q2 2021, Marshall Wace North America held 1,984 positions worth $24.1B, down 0.56% from $24.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Marshall Wace North America withdrew a net $2.11B in Q2 2021, closing 587 positions and reducing 445 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $119M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Marshall Wace North America opened a new position in Syneos Health, Inc. Class A Common Stock worth $83.7M.
- Marshall Wace North America's largest Q2 2021 buy was Syneos Health, Inc. Class A Common Stock: 935,304 shares worth $83.7M.
- Marshall Wace North America added most to Johnson & Johnson in Q2 2021, an estimated $157M increase.
- Marshall Wace North America's biggest Q2 2021 reduction was Microsoft, cutting an estimated $313M.
- Marshall Wace North America fully exited State Street SPDR S&P 500 ETF Trust in Q2 2021, selling an estimated $119M.
- Marshall Wace North America's ten largest holdings make up 24% of its $24.1B portfolio in Q2 2021.
- Marshall Wace North America opened 527 new positions and closed 587 in Q2 2021.
- Marshall Wace North America's portfolio value fell 0.56% quarter-over-quarter to $24.1B.
Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.